Firstly, the subgroup of patients with PD-L1 TC3/IC3 possesses a specific tumor microenvironment where the tumor cells themselves and the surrounding immune cells collectively suppressed CD8+ cytotoxic T lymphocytes (CTLs)-mediated immune surveillance and attacked their high PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.